Publications
2026
Chong SJF, Valentin R, Wang J, Zhu F, Gokhale PC, Eschle BK, Garbicz F, Iskandar K, Sewastianik T, Toh BCY, Penailillo J, Peluso MO, Zhang J, Hackett L, Collins MC, Lehmberg TZ, Adam A, Zhang L, Armet CM, Rausch M, Lee BH, Holland PM, Palombella VJ, Paterson AM, Kong LR, Ten Hacken E, Guerriero JL, Herbaux C, Wu CJ, Chng WJ, Pervaiz S, Niemann CU, Carrasco RD, Davids MS. CD47 blockade-driven necroptosis complements BCL-2 inhibition-driven apoptosis in lymphoid malignancies. J Hematol Oncol. 2026 Jan 3;19(1):11. doi: 10.1186/s13045-025-01774-3. PMID: 41484790; PMCID: PMC12810019.
View in: PubMed pubmed.ncbi.nlm.nih.gov/41484790/
Davids Lab Author(s): Matthew Davids, Stephen Chong, Rebecca Valentin, Jing Wang, Fen Zhu, Jeremy Zhang, Liam Hackett, Mary Collins, Tim Lehmberg, Charles Herbaux
View in: PubMed pubmed.ncbi.nlm.nih.gov/41484790/
Davids Lab Author(s): Matthew Davids, Stephen Chong, Rebecca Valentin, Jing Wang, Fen Zhu, Jeremy Zhang, Liam Hackett, Mary Collins, Tim Lehmberg, Charles Herbaux
2025
Chong SJF, Lu J, Valentin R, Lehmberg TZ, Eu JQ, Wang J, Zhu F, Kong LR, Fernandes SM, Zhang J, Herbaux C, Goh BC, Brown JR, Niemann CU, Huber W, Zenz T, Davids MS. BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia. Mol Cancer. 2025 Mar 3;24(1):62. doi: 10.1186/s12943-025-02260-7. PMID: 40025512; PMCID: PMC11874845.
View in: Molecular Cancer pubmed.ncbi.nlm.nih.gov/40025512/
Davids Lab Author(s): Matthew Davids, Stephen Chong, Rebecca Valentin, Tim Lehmberg, Jing Wang, Fen Zhu, Jeremy Zhang, Charles Herbaux
View in: Molecular Cancer pubmed.ncbi.nlm.nih.gov/40025512/
Davids Lab Author(s): Matthew Davids, Stephen Chong, Rebecca Valentin, Tim Lehmberg, Jing Wang, Fen Zhu, Jeremy Zhang, Charles Herbaux
Jacquier V, Romero A, Molinaro C, Somayaji R, Abouladze M, Gadacha OK, Ovejero S, de Boussac H, Gabellier L, Davids MS, Moreaux J, Herbaux C. Development of a robust BH3 drug toolkit for precision medicine in hematologic malignancies. Theranostics. 2025 Apr 21;15(12):5705-5718. doi: 10.7150/thno.107852. PMID: 40365276; PMCID: PMC12068295.
View in: Theranostics pubmed.ncbi.nlm.nih.gov/40365276/
Davids Lab Author(s): Matthew Davids, Charles Herbaux, Ritu Somayaji
View in: Theranostics pubmed.ncbi.nlm.nih.gov/40365276/
Davids Lab Author(s): Matthew Davids, Charles Herbaux, Ritu Somayaji
2024
Davids MS, Brander DM, Valero YA, Diefenbach CS, Egan DN, Dinner SN, Javidi-Sharifi N,Al Malki MM, Begna K,Bhatt VR, Abedin S, Cook R, Collins MC, Roleder C, Dominguez EC, Rajagopalan P, Wiley SE, Ghalie RG, Danilov AV. A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies. Blood Adv2024; bloodadvances.2024014633. doi: https://doi.org/10.1182/bloodadvances.2024014633.
View in: Blood Advances
Davids Lab Author(s): Matthew Davids, Nathalie Javidi-Sharifi, Mary Collins
View in: Blood Advances
Davids Lab Author(s): Matthew Davids, Nathalie Javidi-Sharifi, Mary Collins
Davids MS, Ryan CE et al. Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease. JCO 0, JCO-24-02503. DOI:10.1200/JCO-24-02503.
View in: Journal of Clinical Oncology
Davids Lab Author(s): Matthew Davids, Christine Ryan
View in: Journal of Clinical Oncology
Davids Lab Author(s): Matthew Davids, Christine Ryan
Lakhani NJ, Rasco D, Wang H, Men L, Liang E, Fu T, Collins MC, Min P, Yin Y, Davids MS, Yang D, Zhai Y. First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res 1 February 2024; 30 (3): 506–521. https://doi.org/10.1158/1078-0432.CCR-23-1525
View in: Clinical Cancer Research
Davids Lab Author(s): Matthew Davids, Mary Collins
View in: Clinical Cancer Research
Davids Lab Author(s): Matthew Davids, Mary Collins
2023
Ryan, CE, Brander, DM, Barr, PM et al. A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia. 37, 835–842 (2023)
View in: PubMed
Davids Lab Author(s): Christine Ryan, Liam Hackett, Mary Collins, Matthew Davids
View in: PubMed
Davids Lab Author(s): Christine Ryan, Liam Hackett, Mary Collins, Matthew Davids
Chong SJF, Zhu F, Dashevsky O, Mizuno R, Lai JX, Hackett L, Ryan CE, Collins MC, Iorgulescu JB, Guièze R, Penailillo J, Carrasco R, Hwang YC, Muñoz DP, Bouhaddou M, Lim YC, Wu CJ, Allan JN, Furman RR, Goh BC, Pervaiz S, Coppé JP, Mitsiades CS, Davids MS. Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies. J Clin Invest. 2023 Sep 26. PMID: 37751299.
View in: PubMed
Davids Lab Author(s): Stephen Chong, Christine Ryan, Mary Collins, Liam Hackett, Fen Zhu, Matthew Davids
View in: PubMed
Davids Lab Author(s): Stephen Chong, Christine Ryan, Mary Collins, Liam Hackett, Fen Zhu, Matthew Davids
Zhu F, Crombie JL, Ni W, Hoang NM, Garg S, Hackett L, Chong SJF, Collins MC, Rui L, Griffin J, Davids MS. Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax. Haematologica. 2023 Aug 03. PMID: 37534528.
View in: PubMed
Davids Lab Author(s): Fen Zhu, Liam Hackett, Stephen Chong, Mary Collins, Matthew Davids
View in: PubMed
Davids Lab Author(s): Fen Zhu, Liam Hackett, Stephen Chong, Mary Collins, Matthew Davids
Ryan CE, Davids MS. Practical Management of Richter Transformation in 2023 and Beyond. Am Soc Clin Oncol Educ Book. 2023 Jan; 43:e390804
View in: PubMed
Davids Lab Author(s): Christine Ryan, Matthew Davids
View in: PubMed
Davids Lab Author(s): Christine Ryan, Matthew Davids
2022
Ryan CE et al. Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease. Blood. 2022 Nov 15.
View in: PubMed
Davids Lab Author(s): Christine Ryan, Liam Hackett, Matthew Davids
View in: PubMed
Davids Lab Author(s): Christine Ryan, Liam Hackett, Matthew Davids
2021
Ngoi NY, Liew AQ, Chong SJF, Davids MS, Clement MV, Pervaiz S. The redox-senescence axis and its therapeutic targeting. Redox Biol. 2021 09; 45:102032. PMID: 34147844.
View in: PubMed
Davids Lab Author(s): Stephen Chong, Matthew Davids
View in: PubMed
Davids Lab Author(s): Stephen Chong, Matthew Davids
Kornauth C, Herbaux C, Boidol B, Guillemette C, Caron P, Mayerhöfer ME, Poulain S, Tournilhac O, Pemovska T, Chong SJF, Van der Kouwe E, Kazianka L, Hopfinger G, Heintel D, Jäger R, Raderer M, Jäger U, Simonitsch-Klupp I, Sperr WR, Kubicek S, Davids MS, Staber PB. Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. Haematologica. 2021 Feb 25
View in: PubMed
Davids Lab Author(s): Charles Herbaux, Stephen Chong, Matthew Davids
View in: PubMed
Davids Lab Author(s): Charles Herbaux, Stephen Chong, Matthew Davids
Herbaux C, Kornauth C, Poulain S, Chong SJF, Collins MC, Valentin R, Hackett L, Tournilhac O, Lemonnier F, Dupuis J, Daniel A, Tomowiak C, Laribi K, Renaud L, Roos-Weil D, Rossi C, Van Den Neste EW, Leyronnas C, Merabet F, Malfuson JV, Tiab M, Ysebaert L, Ng SY, Morschhauser F, Staber PB, Davids MS. BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. Blood. 2021 Feb 17:blood.2020007303.
View in: PubMed
Davids Lab Author(s): Charles Herbaux, Stephen Chong, Mary Collins, Rebecca Valentin, Liam Hackett, Matthew Davids
View in: PubMed
Davids Lab Author(s): Charles Herbaux, Stephen Chong, Mary Collins, Rebecca Valentin, Liam Hackett, Matthew Davids
2020
Chong SJF, Iskandar K, Lai JXH, Qu J, Raman D, Valentin R, Herbaux C, Collins M, Low ICC, Loh T, Davids M, Pervaiz S. Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolism. Nucleic Acids Res. 2020 Nov 27:gkaa1110.
View in: PubMed
Davids Lab Author(s): Stephen Chong, Rebecca Valentin, Charles Herbaux, Mary Collins, Matthew Davids
View in: PubMed
Davids Lab Author(s): Stephen Chong, Rebecca Valentin, Charles Herbaux, Mary Collins, Matthew Davids
Chong SJF, Davids MS. Breaking through BCL-2 inhibition in CLL. Blood. 2020 Mar 05; 135(10):709-711.
View in: PubMed
Davids Lab Author(s): Stephen Chong, Matthew Davids
View in: PubMed
Davids Lab Author(s): Stephen Chong, Matthew Davids
2019
Ryan CE, Davids MS. BCL-2 Inhibitors, Present and Future. Cancer J. 2019 Nov/Dec; 25(6):401-409.
View in: PubMed
Davids Lab Author(s): Matthew Davids, Christine Ryan
View in: PubMed
Davids Lab Author(s): Matthew Davids, Christine Ryan
Herbaux C, Davids MS. Venetoclax: R-CHOP rocket booster? Blood. 2019 05 02; 133(18):1922-1924.
View in: PubMed
Davids Lab Author(s): Charles Herbaux, Matthew Davids
View in: PubMed
Davids Lab Author(s): Charles Herbaux, Matthew Davids
2018
Ten Hacken E, Valentin R, Regis FFD, Sun J, Yin S, Werner L, Deng J, Gruber M, Wong J, Zheng M, Gill AL, Seiler M, Smith P, Thomas M, Buonamici S, Ghia EM, Kim E, Rassenti LZ, Burger JA, Kipps TJ, Meyerson ML, Bachireddy P, Wang L, Reed R, Neuberg D, Carrasco RD, Brooks AN, Letai A, Davids MS, Wu CJ. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018 10 04; 3(19).
View in: PubMed
Davids Lab Author(s): Rebecca Valentin, Matthew Davids, Rebecca Valentin
View in: PubMed
Davids Lab Author(s): Rebecca Valentin, Matthew Davids, Rebecca Valentin
Valentin R, Grabow S, Davids MS. The rise of apoptosis: targeting apoptosis in hematologic malignancies. Blood. 2018 09 20; 132(12):1248-1264.
View in: PubMed
Davids Lab Author(s): Rebecca Valentin, Stephanie Grabow, Matthew Davids
View in: PubMed
Davids Lab Author(s): Rebecca Valentin, Stephanie Grabow, Matthew Davids
2017
Deng J, Isik E, Fernandes SM, Brown JR, Letai A, Davids MS. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia. 2017 10; 31(10):2075-2084.
View in: PubMed
Davids Lab Author(s): Matthew Davids
View in: PubMed
Davids Lab Author(s): Matthew Davids